Pharma M&A versus alliances and its underlying value drivers: Are M&A or alliances the right therapy for an ailing pharmaceutical industry?- A capital ... (15) (Corporate Finance and Governance) - Hardcover
Inhaltsangabe
This study analyzes 229 M&A and 120 in-licensing deals in the pharmaceutical industry. The author shows from a capital market perspective that M&A experiences significant, negative cumulative average abnormal returns whereas in-licensings are able to create value. Significant determinants of success for both strategies are derived.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Über die Autorin bzw. den Autor
Heiko Schön studied international business administration at Wiesbaden Business School. He was scholar of the German National Merit Foundation (sdw), he owns an Executive MBA from the University of Münster and earned his PhD at the University of Darmstadt. He brings in 10 years of experience in the pharmaceutical and chemical industry.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Suchergebnisse für Pharma M&A versus alliances and its underlying...
Beispielbild für diese ISBN
Pharma MandA versus alliances and its underlying value drivers
Anbieter: PBShop.store UK, Fairford, GLOS, Vereinigtes Königreich
Verkäuferbewertung 5 von 5 Sternen
HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000. Artikel-Nr. CX-9783631663813
Neu kaufen
EUR 54,19
Versand:
EUR 4,71
Von Vereinigtes Königreich nach USA
Anzahl: 15 verfügbar
Foto des Verkäufers
Pharma m&a versus alliances and its underlying value drivers : are m&a or alliances the right therapy for an ailing pharmaceutical industry? ; a capital market perspective. Corporate finance and governance ; Vol. 15
Verlag:
Frankfurt, M. : PL Acad. Research, 2015
ISBN 10: 3631663811
ISBN 13: 9783631663813
Gebraucht
Hardcover
Anbieter: Fundus-Online GbR Borkert Schwarz Zerfaß, Berlin, Deutschland
Verkäuferbewertung 5 von 5 Sternen
Pp. Zustand: Wie neu. 201 S. : graph. Darst. ; 22 cm, 360 g Tadellos. - Content -- Table Index 9 -- Graph Index 11 -- A. Introduction 15 -- I. The Pharmaceutical Industry and Its Paradigm Shift 19 -- 1.1 History 19 -- 1.2 Market Analysis 20 -- 1.2.1 Market Definition 20 -- 1.2.2 Market Size and Market Growth 21 -- 1.2.3 BigPharma 21 -- 1.2.4 Geographic Segmentation 22 -- 1.2.5 Therapeutic Segmentation 24 -- 1.2.6 Blockbusters 25 -- 1.3 Innovation and Innovation Crisis 26 -- 1.3.1 R&D Productivity 27 -- 1.3.2 R&D Process 28 -- 1.3.3 R&D Pipeline 30 -- 1.4 Patent Protection and Patent Cliff 32 -- 1.5 Generics 34 -- 1.6 Biotechnology 37 -- 1.7 Pricing, Funding and Governmental Austerity Measures 41 -- 1.8 Restructuring Programs 43 -- 1.9 Summary 44 -- II. The Pharmaceutical Industry and Mergers & Acquisitions 47 -- II.1 M&A Deal Rationales 47 -- II.1.1 Scale & Synergy Deals 48 -- II.1.2 Innovation Deals 50 -- II.1.3 Pharmerging Market Deals 51 -- II.1.4 Diversification Deals 52 -- 11.2 Status of Consolidation 53 -- 11.3 M&A Activity Development 54 -- 11.4 Top Pharmaceutical M&A Transactions 56 -- 11.5 Summary 59 -- III. Value Creation in Pharmaceutical M&A and its -- underlying Value Drivers 61 -- III.1 Literature Review and Literature Contribution 61 -- 111.2 Data Sample 62 -- 111.3 Deal Statistics 65 -- 111.4 Research Methodology. 66 -- 111.5 Acquirers'Wealth Effects 73 -- 111.6 Univariate Subsample Analyses of M&A Value Drivers 74 -- III.6.1 Target's Business Nature 74 -- 111.6.2 Geographical Focus 80 -- 111.6.3 Pharmaceutical Merger Waves 87 -- 111.6.4 Relative Transaction Size 89 -- 111.6.5 Method of Payment 92 -- 111.6.6 Target's R&D Intensity 94 -- 111.6.7 Strategic Alliances Pre-Merger 96 -- 111.6.8 M&A Experience 100 -- 111.6.9 Relative Price Level 102 -- 111.6.10 Target's Financials 106 -- 111.7 Multivariate Analysis of M&A Value Drivers 113 -- 111.8 Conclusions and Recommendations 117 -- IV. The Pharmaceutical Industry and Alliances 119 -- IV.1 Strategic Alliances 119 ISBN 9783631663813 Sprache: Englisch Gewicht in Gramm: 315. Artikel-Nr. 1076637
Gebraucht kaufen
EUR 19,92
Versand:
EUR 40,00
Von Deutschland nach USA
Anzahl: 1 verfügbar
Foto des Verkäufers
Pharma M&A versus alliances and its underlying value drivers
Verlag:
Peter Lang, Peter Lang Sep 2015, 2015
ISBN 10: 3631663811
ISBN 13: 9783631663813
Neu
Hardcover
Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschland
Verkäuferbewertung 5 von 5 Sternen
Buch. Zustand: Neu. Neuware -From a capital market perspective, the author analyzes Merger and Acquisitions transactions (M&A) and in-licensings in the pharmaceutical industry between 1998 and 2012. Utilizing the event study methodology, the volume shows that M&A experiences significant, negative cumulative average abnormal returns whereas in-licensings are able to create value. But what are the underlying value drivers which make a deal a success or a failure story The author derives significant innovative determinants of success for both strategies. 202 pp. Englisch. Artikel-Nr. 9783631663813
Neu kaufen
EUR 67,75
Versand:
EUR 60,00
Von Deutschland nach USA
Anzahl: 2 verfügbar
Foto des Verkäufers
Pharma M&A versus alliances and its underlying value drivers : Are M&A or alliances the right therapy for an ailing pharmaceutical industry?- A capital market perspective
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Verkäuferbewertung 5 von 5 Sternen
Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - From a capital market perspective, the author analyzes Merger and Acquisitions transactions (M&A) and in-licensings in the pharmaceutical industry between 1998 and 2012. Utilizing the event study methodology, the volume shows that M&A experiences significant, negative cumulative average abnormal returns whereas in-licensings are able to create value. But what are the underlying value drivers which make a deal a success or a failure story The author derives significant innovative determinants of success for both strategies. Artikel-Nr. 9783631663813
Neu kaufen
EUR 67,75
Versand:
EUR 61,90
Von Deutschland nach USA
Anzahl: 1 verfügbar